Delivery of lipophilic compounds with lipid nanoparticles - applications in dermatics and for transdermal therapy

Lipospheres in Drug Targets and Delivery: Approaches, Methods, and Applications

Volumn , Issue , 2004, Pages 127-142

  Schäfer Korting, Monika ^a   Mehnert, Wolfgang ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056314958     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203505281     Document Type: Chapter

References (70)

1. Bouwstra, J. A., et al., Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res., 42, 1-36, 2003.
2. Barry, B. W., Drug delivery routes in skin: a novel approach. Adv. Drug Deliv. Rev., 54 (Suppl. 1), S31-40, 2002.
3. Hoffman, R. M., Topical liposome targeting of dyes, melanins, genes, and proteins selectively to hair follicles. J. Drug Target., 5, 67-74, 1998.
4. Shah, V. P., Progress in methodologies for evaluating bioequivalence of topical formulations. Am. J. Clin. Dermatol., 2, 275-80, 2001.
5. Müller, R. H. and Lucks, J. S., Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). European Patent, EP 0605497, 1996.
6. Siekmann, B. and Westesen, K., Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett., 1, 123-26, 1992.
7. Müller, R. H., et al., Solid lipid nanoparticles (SLN): an alternative colloidal drug carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm., 41, 1995.
8. Müller, R. H., Mäder, K. and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur. J. Pharm. Biopharm., 50, 161-77, 2000.
9. Mehnert, W. and Mäder, K., Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 47, 165-96, 2001.
10. Müller, R. H., Radtke, M. and Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 54 (Suppl. 1), S131-55, 2002.
11. Speiser, P., Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung. European Patent, EP 0167825, 1990.
12. Domb, A. J., Lipospheres for controlled delivery of substances. United States Patent, US 5,188,337, 1993.
13. Ahlin, P., Kristl, J. and Smid-Kobar, J., Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm., 48, 257-67, 1998.
14. Gasco, M. R., Solid lipid nanospheres from warm microemulsions. Pharm. Technol. Eur., 9, 52-58, 1997.
15. Sjöström, B. and Bergenståhl, B., Preparation of submicron drug partides in lecithinstabilized o/w emulsions. I. Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm., 88, 53-62, 1992.
16. Siekmann, B. and Westesen, K., Electron-microscopic characterization of melthomogenized solid lipid nanoparticles. Eur. J. Pharm. Biopharm., 2, 190, 1994.
17. Dingler, A., et al., Solid lipid nanoparticles (SLN/Lipopearls): a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsul., 16, 751-67, 1999.
18. Dubes, A., et al., Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur. J. Pharm. Biopharm., 55, 279-82, 2003.
19. zur Mühlen, A., et al., Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res., 13, 1411-16, 1996.
20. Westesen, K. and Bunjes, H., Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm., 115, 129-31, 1995.
21. Bunjes, H., Koch, M. H. J. and Westesen, K., Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci., 92, 1509-20, 2003.
22. Siekmann, B. and Westesen, K., Thermoanalysis of the recrystallization of melt-homogenized glyceride nanoparticles. Colloids Surf. B., 3, 159-75, 1994.
23. Laggner, P., X-ray diffraction of lipids, in: Spectral properties of lipids, Hamilton, R. J. and Cast, J., Eds., Sheffield Academic Press, Sheffield, 1999, 327-67.
24. Unruh, T., et al., Observation of size-dependent melting in lipid nanoparticles. J. Phys. Chem. B, 103, 10373-77, 1999.
25. Jenning, V., et al., Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm., 49, 211-18, 2000.
26. Jenning, V., Mäder, K. and Gohla, S. H., Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a 1H-NMR study. Int. J. Pharm., 205, 15-21, 2000.
27. Jores, K., Mehnert, W. and Mäder, K., Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm. Res., 20, 1274-83, 2003.
28. Ahlin, P., Kristl, J. and Sentjurc, M., EPR study of loading capacity of spin-labelled lipophilic substance in different SLN. Proc. Int. Symp. Control. Release Bioact. Mater., 25, 334-35, 1998.
29. zur Mühlen, A., Schwarz, C. and Mehnert, W., Solid lipid nanoparticles (SLN) for controlled drug delivery: drug release and release mechanism. Eur. J. Pharm. Biopharm., 45, 149-55, 1998.
30. zur Mühlen, A. and Mehnert, W., Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie, 53, 552-55, 1998.
31. Olbrich, C. and Müller, R. H., Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 180, 31-39, 1999.
32. Freitas, C. and Müller, R. H., Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J. Microencapsul., 16, 59-71, 1999.
33. Bunjes, H., Westesen, K. and Koch, M. H. J., Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm., 129, 159-73, 1996.
34. Freitas, C. and Müller, R. H., Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 47, 125-32, 1999.
35. Westesen, K. and Siekmann, B., Investigation of the gel formation of phospholipidstabilized solid lipid nanoparticles. Int. J. Pharm., 151, 35-45, 1997.
36. FDA Guidance: Topical dermatologic corticosteroids: in vivo bioequivalence, available online at http://www.fda.gov/cder/guidance/old098fn.pdf, June 2, 1995.
37. OECD, Skin absorption: in vitro method. OECD Test Guideline 428, Paris, 2004.
38. Wagner, H., et al., Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data. Pharm. Res., 17, 1475-81, 2000.
39. Jenning, V. and Gohla, S. H., Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul., 18, 149-58, 2001.
40. de Vringer, T. and de Ronde, H. A. G., Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci., 84, 466-72, 1995.
41. Wissing, S. A., Lippacher, A. and Müller, R. H., Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J. Cosmet. Sci., 52, 313-24, 2001.
42. Weiner, N., Targeted follicular delivery of macromolecules via liposomes. Int. J. Pharm., 162, 29-38, 1998.
43. Otberg, N., et al., Visualization of topically applied fluorescent dyes in hair follicles by laser scanning microscopy. Laser Phys., 13, 761-64, 2003.
44. Grams, Y. Y. and Bouwstra, J. A., Penetration and distribution of three lipophilic probes in vitro in human skin focusing on the hair follicle. J. Control. Release, 83, 253-62, 2002.
45. Santos Maia, C., et al., Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Targeting, 10, 489-95, 2002.
46. Mezei, M. and Gulasekharam, V., Liposomes: a selective drug delivery system for the topical route of administration: gel dosage form. J. Pharm. Pharmacol., 34, 473-74, 1982.
47. Mezei, M. and Gulasekharam, V., Liposomes - a selective drug delivery system for the topical route of administration: lotion dosage form. Life Sci., 26, 1473-77, 1980.
48. Fresta, M. and Puglisi, G., Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5I-diphosphate choline. Life Sci., 61, 1227-35, 1997.
49. Korting, H. C., Vieluf, D. and Kerscher, M., 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur. J. Clin. Pharmacol., 42, 159-61, 1992.
50. Schäfer-Korting, M., Schmid, M. H. and Korting, H. C., Topical glucocorticoids with improved risk-benefit ratio: rationale of a new concept. Drug Saf., 14, 375-85, 1996.
51. Egbaria, K., Ramachandran, C. and Weiner, N., Topical application of liposomally entrapped cyclosporin evaluated by in vitro diffusion studies with human skin. Skin Pharmacol., 4, 21-28, 1991.
52. Erdogan, M., Wright, J. R., Jr. and McAlister, V. C., Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br. J. Dermatol., 146, 964-67, 2002.
53. Masini, V., et al., Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. J. Pharm. Sci., 82, 17-21, 1993.
54. Michel, C., et al., Penetration of spin-labeled retinoic acid from liposomal preparations into the skin of SKH1 hairless mice: measurement by EPR tomography. Int. J. Pharm., 98, 131-39, 1993.
55. Schäfer-Korting, M., Korting, H. C. and Ponce-Pöschl, E., Liposomal tretinoin for uncomplicated acne vulgaris. Clin. Investig., 72, 1086-91, 1994.
56. Jenning, V., Schäfer-Korting, M. and Gohla, S., Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J. Control. Release, 66, 115-26, 2000.
57. Yarosh, D., et al., Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Lancet, 357, 926-29, 2001.
58. Yarosh, D. B., Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed., 17, 203-12, 2001.
59. Paul, A., Cevc, G. and Bachhawat, B. K., Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine, 16, 188-95, 1998.
60. Baca-Estrada, M. E., et al., Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine, 18, 1847-54, 2000.
61. Schaller, M., Korting, H. C. and Schmid, M. H., Interaction of cultured human keratinocytes with liposomes encapsulating silver sulphadiazine: proof of the uptake of intact vesicles. Br. J. Dermatol., 134, 445-50, 1996.
62. Birchall, J. C., et al., Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes. Int. J. Pharm., 197, 233-38, 2000.
63. Williams, D. A. and Baum, C., Medicine: gene therapy - new challenges ahead. Science, 302, 400-01, 2003.
64. Hacein-Bey-Abina, S., et al., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415-19, 2003.
65. Choi, M. J. and Maibach, H. I., Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol. Appl. Skin Physiol., 16, 271-82, 2003.
66. Fimmel, S., et al., Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells. Horm. Res., 54, 306-11, 2000.
67. Bielinska, A. U., et al., Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials, 21, 877-87, 2000.
68. Wissing, S. A. and Müller, R. H., The influence of solid lipid nanoparticles on skin hydration and viscoelasticity: in vivo study. Eur. J. Pharm. Biopharm., 56, 67-72, 2003.
69. Schreurs, R., et al., Estrogenic activity of UV filters determined by an in vitro reporter gene assay and an in vivo transgenic zebrafish assay. Arch. Toxicol., 76, 257-61, 2002.
70. Schlumpf, M., et al., In vitro and in vivo estrogenicity of UV screens. Environ. Health Perspect., 109, 239-44, 2001.